MESO Stock Analysis: Buy, Sell, or Hold?
MESO - Mesoblast Limited American Depositary Shares
$14.38
0.29 (2.06%)
▲
5d:
-0.83%
30d:
-0.96%
90d:
-8.99%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 27, 2026
Get Alerted When MESO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MESO shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: MESO shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: MESO is currently trading at $14.38, which is considered fair relative to its 30-day fair value range of $13.74 to $15.00. From a valuation perspective, the stock is trading at a discount (Forward PE: -205.4) compared to its historical average (206.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MESO is in a downtrend. Immediate support is located at $13.05, while resistance sits at $15.88.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $35.00 (+143.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MESO is in a downtrend. Immediate support is located at $13.05, while resistance sits at $15.88.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $35.00 (+143.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$13.74 -
$15.00
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 143.4% below Wall St target ($35.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$13.74 -
$15.00
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$13.05
Resistance Level
$15.88
Current Trend
Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-205.43
Wall Street Target
$35.00
(+143.4%)
Revenue Growth (YoY)
1526.8%
Profit Margin
-144.3%
PE vs Historical
-205.4 vs 206.7
CHEAP
Share & Embed Analysis
Last updated: July 03, 2026 8:33 PM ET
Data refreshes hourly during market hours. Next update: 9:33 PM
Data refreshes hourly during market hours. Next update: 9:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MESO showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Gregory George
BUY
2324072 shares
2026-04-10
Gregory George
BUY
1586890 shares
2026-04-09
Gregory George
BUY
1981890 shares
2026-04-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
